Mahesh Karande (Omega)
'Exquisite control': Flagship pulls off $85M rally around Omega Therapeutics' clinical push for epigenetic programming tech
Omega Therapeutics began, as all biotech fledglings incubated at Flagship Labs do, with an off-the-wall question: Can one control gene expression but not create the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.